文献速递介入腹部泌尿生殖PETCTSPECT

乳腺癌肝转移放射性栓塞治疗中辐射剂量与疗效的关系

Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer.
PubMed 文献 · Eur J Radiol · 2021-01-12

这项回顾性研究评估了64例接受经动脉放射性栓塞(TARE)的乳腺癌肝转移患者,发现客观缓解者(46/60,77%)接受的肿瘤辐射剂量中位数167 Gy显著高于未缓解者的54 Gy(p<0.001),肿瘤剂量>79.5 Gy与客观缓解相关,客观缓解与更长总生存相关(17个月 vs 10个月,p=0.027);≥3级肝毒性与治疗前胆红素较高相关,并与生存期缩短相关。

要点

  • 肿瘤辐射剂量>79.5 Gy与客观缓解相关,缓解者中位肿瘤剂量167 Gy vs 未缓解者54 Gy(p<0.001)。
  • 双叶病变(HR 2.77)和治疗前AST升高(HR 1.02)与更短生存独立相关。
  • ≥3级肝毒性发生率12.5%,与治疗前胆红素较高相关(0.9 vs 0.5 mg/dL,p=0.013)。

核心结论

  • 乳腺癌肝转移TARE中,较高的肿瘤辐射剂量(>79.5 Gy)与客观缓解相关,客观缓解与更长生存相关;治疗前肝功能不全与肝毒性相关,肝毒性与生存期缩短相关。

研究设计与样本

  • 回顾性研究,纳入2011年2月至2019年6月接受TARE的乳腺癌肝转移患者64例,其中60例有TARE前后PET/CT;基线PET/CT评估单叶或双叶病变,TARE后Bremsstrahlung SPECT/CT进行容积分割以评估肿瘤及非肿瘤肝剂量;采用修改版PERCIST标准评估靶区域缓解;≥3级肝毒性定义为胆红素/AST/ALT升高≥3级或需干预的腹水;统计方法包括Fisher精确检验、Wilcoxon秩和检验和Kaplan-Meier生存分析。

诊断标准与关键数值

  • 客观缓解定义为靶区域按修改版PERCIST标准评估;缓解者中位肿瘤剂量167(96-217)Gy vs 未缓解者54(45-62)Gy(p<0.001);肿瘤剂量>79.5 Gy与客观缓解相关;≥3级肝毒性定义为胆红素/AST/ALT升高≥3级或需干预的腹水,发生率8/64(12.5%);≥3级肝毒性者治疗前胆红素0.9(0.9-1.1)mg/dL vs 无≥3级肝毒性者0.5(0.4-0.7)mg/dL(p=0.013);中位总生存11个月(95%CI 10-19);双叶病变HR 2.77(95%CI 1.11-6.89,p=0.028),治疗前AST升高HR 1.02(95%CI 1.01-1.03,p<0.001);客观缓解者中位总生存17个月 vs 未缓解者10个月(p=0.027)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the relationship of tumoral and nontumoral radiation dose to response and toxicity after transarterial radioembolization (TARE) of breast cancer liver metastasis.

METHODS: This retrospective study evaluated all patients with breast cancer liver metastases treated with TARE (2/2011-6/2019). Extent of disease was measured as unilobar or bilobar on baseline PET/CT prior to TARE. Response was assessed for targeted regions with modified PERCIST criteria on first follow-up PET/CT. Tumoral and nontumoral liver dosimetry was evaluated by performing volumetric segmentation on post-TARE Bremsstrahlung SPECT/CT. ≥Grade 3 hepatotoxicity was defined as ≥grade 3 bilirubin/AST/ALT elevation or ascites requiring intervention. Fisher's exact tests, Wilcoxon rank sum tests, and Kaplan-Meier survival analysis were performed.

RESULTS: Among 64 women, 60 patients had pre- and post-TARE PET/CT, of whom 46/60 (77 %) achieved objective response (OR). Responders received higher tumoral dose with a median (interquartile range) of 167 (96-217) vs. 54 (45-62) Gy (p < 0.001). ≥Grade 3 hepatotoxicity occurred in 8/64 (12.5 %) and was associated with higher pre-treatment bilirubin levels of 0.9 (0.9-1.1) vs. 0.5 (0.4-0.7) mg/dL (p = 0.013). Median overall survival (OS) was 11 (95 % CI 10-19) months. Bilobar disease (Hazard Ratio [HR]: 2.77, 95 % CI 1.11-6.89, p = 0.028) and elevated pre-TARE AST (HR 1.02, 95 % CI 1.01-1.03, p < 0.001) were independently associated with shorter survival. ≥Grade 3 hepatotoxicity was associated with reduced survival (p < 0.001). OR was associated with longer OS of 17 months, compared with 10 months (p = 0.027).

CONCLUSION: In TARE for breast cancer liver metastasis, higher tumoral radiation dose (>79.5 Gy) was associated with OR, which was associated with longer survival. Pre-existing liver dysfunction was associated with hepatotoxicity, which was associated with decreased survival.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ridouani F, Soliman MM, England RW, et al. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer. Eur J Radiol. 2021. PMID: 33476965. doi:10.1016/j.ejrad.2021.109539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。